Comprehensive analysis of “bath salts” purchased from California stores and the internet

References

• Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011; 49:499–505.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as “bath salts”–Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:624–627.
   PubMedGoogle Scholar
• Warrick BJ, Hill M, Hekman K, Christensen R, Goetz R, Casavant MJ, et al. A 9-state analysis of designer stimulant, “Bath Salt,” hospital visits reported to poison control centers. Ann Emerg Med 2013 Mar 20.
   Web of Science ®Google Scholar
• Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 2012; 8:69–75.
   PubMedGoogle Scholar
• Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 2012; 60:103–105.
   PubMed Web of Science ®Google Scholar
• Murphy CM, Dulaney AR, Beuhler MC, Kacinko S.“Bath salts” and “plant food” products: the experience of one regional US poison control center. J Med Toxicol 2013; 9:42–48.
   PubMedGoogle Scholar
• Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing ‘legal highs’ on the Internet–is there consistency in what you get? QJM 2010; 103:489–493.
   PubMed Web of Science ®Google Scholar
• Davies S, Lee T, Ramsey J, Dargan PI, Wood DM. Risk of caffeine toxicity associated with the use of ‘legal highs’ (novel psychoactive substances). Eur J Clin Pharmacol 2012; 68:435–439.
   PubMed Web of Science ®Google Scholar
• Ramsey J, Dargan PI, Smyllie M, Davies S, Button J, Holt DW, Wood DM. Buying ‘legal’ recreational drugs does not mean that you are not breaking the law. QJM 2010; 103:777–783.
   PubMed Web of Science ®Google Scholar
• Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second- generation ‘legal highs’ in the UK: initial findings. Drug Test Anal. 2010; 2:377–382.
   PubMed Web of Science ®Google Scholar
• Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test Anal 2011; 3:569–575.
   PubMed Web of Science ®Google Scholar
• Baron M, Elie M, Elie L. An analysis of legal highs: do they contain what it says on the tin? Drug Test Anal 2011; 3:576–581.
   PubMed Web of Science ®Google Scholar
• Ayres TC, Bond JW. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill)health. Legal highs or illegal highs? BMJ Open 2012;2.
   Google Scholar
• Reitzel LA, Dalsgaard PW, Muller IB, Cornett C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish internet company. Drug Test Anal 2012; 4:342–354
   PubMed Web of Science ®Google Scholar
• Corkery JM, Elliot S, Schifano F, Corazza OR, Ghodse AH. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a preliminary review. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:253–258.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012; 36:360–371.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Fed Regist 2011; 76:65371–65375.
   PubMedGoogle Scholar
• Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012; 8:310–313.
   PubMedGoogle Scholar
• Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Analy Toxicol 2013; 37:135–146.
   PubMed Web of Science ®Google Scholar
• Gerona RR, Wu AH. Bath salts. Clin Lab Med. 2012; 32:415–427.
   PubMed Web of Science ®Google Scholar
• Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012; 50:733–742.
   PubMed Web of Science ®Google Scholar
• Polettini A, Gottardo R, Pascali JP, Tagliaro F. Implementation and performance evaluation of a database of chemical formulas for the screening of pharmaco/toxicologically relevant compounds in biological samples using electrospray ionization-time-of-flight mass spectrometry. Anal Chem 2008; 80:3050–3057.
   PubMed Web of Science ®Google Scholar
• Guale F, Shahreza S, Walterscheid JP, Chen HH, Arndt C, Kelly AT, Mozayani A. Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 2013; 37:17–24.
   PubMed Web of Science ®Google Scholar
• Federal Analog Act. Available at: http://www.gpo.gov/fdsys/pkg/USCODE-2008-title21/pdf/USCODE-2008-title21-chap13-subchapI-partB-sec813.pdf (Accessed on April 10th, 2014).
   Google Scholar
• Dickson Amber J, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Analyt Toxicol 2010; 34:162–168.
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26:536–539.
   PubMed Web of Science ®Google Scholar
• Pederson AJ, Petersen TH, Linnet K. In vitro metabolism and pharmacokinetics studies on methylone. Drug Metab Dispos 2013; 41:1247–1255
   PubMed Web of Science ®Google Scholar
• Meyer MR, Peng D, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010;45: 1426–1442.
   PubMed Web of Science ®Google Scholar
• Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 2009; 44:952–964.
   PubMed Web of Science ®Google Scholar
• Pedersen AJ, Reitzel LA, Johansen SS, Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 2013; 5:430–438.
   PubMed Web of Science ®Google Scholar
• Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163:213–216.
   PubMed Web of Science ®Google Scholar
• Synthetic Drug Abuse Prevention Act of 2012. Congressional Record-112th Congress (2011–2012). Available at: http://www.gpo.gov/fdsys/pkg/BILLS-112s3190is/pdf/BILLS-112s3190is.pdf. Accessed June 19, 2014.
   Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: extension of temporary placement of methylone into schedule I of the Controlled Substances Act. Final order. Fed Regist 2012; 77: 64032–64033.
   PubMedGoogle Scholar
• Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009; 104:2057–2066.
   PubMed Web of Science ®Google Scholar
• Teng SF, Wu SC, Liu C, Li JH, Chien CS. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci Int2006; 161:202–208.
   PubMed Web of Science ®Google Scholar
• Wood DM, Stribley V, Dargan PI, Davies S, Holt DW, Ramsey J. Variability in the 3,4-methylenedioxymethamphetamine content of ‘ecstasy’ tablets in the UK. Emerg Med J 2011; 28:764–765.
   PubMed Web of Science ®Google Scholar
• Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012; 8:33–42.
   PubMedGoogle Scholar